BioWorld Asia

June 20, 2007

Diamyd Shares Fall On News Of Diabetes Trial Debacle

Diamyd Medical AB lost around 40 percent of its value Monday on news that it had to jettison a Phase II/III clinical trial of Diamyd, a therapeutic vaccine in development for treating autoimmune diabetes.(BioWorld International) Read More

Bill Limiting Hybrid Embryo Research Riles UK Scientists

Genomic Activity Study Produces Some Shockers

EU Trade Leader Delivers Strong Defense For Biotech

BioInvent Seeks Added Support, More Cash To Boost Pipeline

Start-Up Finds Peptide Fix For Annual Flu Vaccine Work

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 2, 2026.

CINP 2026: Prenatal and adolescent stress shape brain vulnerability

BioWorld Science

Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...

Ontrack Therapeutics divulges compounds for neurodegenerative diseases

BioWorld Science

Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.

Neuracle eyes Shanghai IPO as global BCI funding surges

BioWorld

Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...

Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists

BioWorld Science

Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...